JMIRx Med

PubMed-indexed overlay journal for preprints with post-review manuscript marketplace (What is JMIRx?).

Editor-in-Chief:

Edward Meinert, MA (Oxon), MSc, MBA, MPA, MPH, PhD, CEng, FBCS, EUR ING, Professor of Digital Health and Clinical Artificial Intelligence (Translational and Clinical Research Institute), University of Plymouth, United Kingdom


JMIRx Med (ISSN 2563-6316), which has been accepted for indexing in PubMed and PubMed Central, is an innovative overlay journal to  MedRxiv and JMIR Preprints (other preprint servers are invited to join). JMIRx peer-reviews preprints and publishes their revised "version of record" with peer-review reports across a broad range of medical, clinical and related health sciences. Unlike the majority of JMIR journals, papers published in this journal do not require a digital health focus - in fact, most papers we published in the first months of the journal were related to COVID19, but we publish all research that qualifies for preprinting on MedRxiv

Conceived to address the urgent need to make highly relevant scientific information available as early as possible without losing the quality of the peer-reviewed process, this innovative new journal is the first in a new series of “superjournals”. Superjournals (a type of "overlay" journal) sit on top of preprint servers (JMIRx-Med serves MedRxiv and JMIR Preprints), offering peer-review and everything else a traditional scholarly journal does. Our goal is to rapidly peer review and publish a paper. All JMIRx Med papers must have originated as a preprint. 

All JMIRx Med papers are rigorously peer-reviewed, copyedited and XML-tagged. Accepted papers are published along with the related Peer Review Reports and Author Responses to Peer Review Reports, providing an additional layer of transparency to the scholarly publishing process. 

There is no Article Processing Fee directly paid by authors for this journal. JMIRx Med is envisioned as a diamond open access and Plan-P compliant journal, which enables Plan P member universities/institutions and funders to subsidize peer review of preprints and publishing in JMIRx Med. Individual PI-led labs, departments and universities can become institutional members, guaranteeing unlimited peer-review of preprints.

If you are not affiliated with a Plan P member organization, we encourage you to provide Plan P membership details to your administrator or sign up for a Principal Investigator (PI) level membership. Further details provided here.

For a limited time only, authors who opt-in during submission to receive PREreview or PeerRef community peer review for their preprint or refer us to their department head/librarian/funder contact will receive a membership-waiver and may publish the preprint in JMIRx Med at no cost to the author. Referral form provided here.

To submit a preprint to JMIRx, authors can self-nominate their existing preprints for publication (which is the equivalent to a traditional journal submission), using the minimalistic JMIRx-Med submission form that essentially only points to the preprint (the preprint needs to be unpublished and should not be under consideration by a journal).

 

Preprints that have already been peer-reviewed by third-party Plan P accredited peer-review services such as PREreview and PeerRef do not require further peer-review (at the editors' discretion). In the submission process, you can nominate your preprint for a PREreview journal club, which can be used in lieu of traditional peer-review.

 

For more details on other submission pathways (including for papers not in MedRxiv) and peer-review options see How to submit to a JMIRx journal.

For more information on JMIRx please also see our Knowledge Base article "What is JMIRx?".  

 

 

Recent Articles

Article Thumbnail
Original Papers

While pediatric population has largely remained free of severe COVID-19, in some cases SARS-CoV-2 infection has been associated with complications like Multiple Inflammatory Syndrome in children (MIS-C). We mention another a unique form of hepatitis occurring subsequent to asymptomatic infection of SARS-CoV-2, designated by us as COVID-19 Associated Hepatitis in Children (CAH-C) in a subset of children presented with hepatitis

|
Article Thumbnail
Original Papers

Genetic testing can determine familial and personal risks for heritable thoracic aortic aneurysms and dissections (TAD). The 2022 ACC/AHA guidelines for TAD recommend management decisions based on the specific gene mutation. However, many clinicians lack sufficient comfort or insight to integrate genetic information into clinical practice.

|

We are working in partnership with